QbD Group
    The EU Commission Proposes a General Reform of Pharmaceutical Legislation – What it Means for Patients and the Industry

    The EU Commission Proposes a General Reform of Pharmaceutical Legislation – What it Means for Patients and the Industry

    The EU Commission is proposing a general reform of pharmaceutical legislation. Read more about what this means for patients and the industry.

    2023年5月5日1 分钟阅读

    Regulatory Affairs plays a key role in the pharmaceutical industry: from drug development to commercialization. QbD's regulatory team supports clients with large and small molecule products and the more complex ATMPs of both innovative and generic drug manufacturers to ensure that their medicinal product dossier is compiled with great accuracy and registrations are submitted and followed until the end of the procedure. Need support?

    关于作者

    Koen Laenen
    Koen Laenen

    RA Manager Pharma at QbD Group

    Koen manages the Regulatory Affairs Pharma team at QbD Group, guiding pharmaceutical companies through regulatory submissions and lifecycle management.

    Regulatory Affairs services

    Navigate Regulatory Complexity with Confidence

    Navigate complex regulatory landscapes with expert guidance across pharmaceuticals, medical devices, and IVD.

    Read more
    分享本文

    订阅生命科学领域的最新动态

    专家观点直达您的收件箱——选择您的兴趣。

    绝无垃圾邮件。随时取消订阅。

    Keep reading

    Related articles

    我们使用 Cookie 来改善您的体验

    我们使用必要的 Cookie 来保证网站功能,以及可选的分析 Cookie 来改善我们的服务。 阅读我们的 隐私政策Cookie 政策.